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Abstract Short non-lethal ischemic episodes adminis-
tered to hearts prior to (ischemic preconditioning, IPC)
or directly after (ischemic postconditioning, IPost)
ischemic events facilitate myocardial protection. Trans-
ferring coronary effluent collected during IPC treatment
to un-preconditioned recipient hearts protects from lethal
ischemic insults. We propose that coronary IPC effluent
contains hydrophobic cytoprotective mediators acting via
PI3K/Akt-dependent pro-survival signaling at ischemic
reperfusion. Ex vivo rat hearts were subjected to 30 min
of regional ischemia and 120 min of reperfusion. IPC
effluent administered for 10 min prior to index ischemia
attenuated infarct size by C55% versus control hearts
(P \ 0.05). Effluent administration for 10 min at imme-
diate reperfusion (reperfusion therapy) or as a mimetic of
pharmacological postconditioning (remote postcondition-
ing, RIPost) significantly reduced infarct size compared
to control (P \ 0.05). The IPC effluent significantly
increased Akt phosphorylation in un-preconditioned
hearts when administered before ischemia or at reperfu-
sion, while pharmacological inhibition of PI3K/Akt-sig-
naling at reperfusion completely abrogated the
cardioprotection offered by effluent administration.
Fractionation of coronary IPC effluent revealed that
cytoprotective humoral mediator(s) released during the
conditioning phase were of hydrophobic nature as all
hydrophobic fractions with molecules under 30 kDa
significantly reduced infarct size versus the control and
hydrophilic fraction-treated hearts (P \ 0.05). The total
hydrophobic effluent fraction significantly reduced infarct
size independently of temporal administration (before
ischemia, at reperfusion or as remote postconditioning).
In conclusion, the IPC effluent retains strong cardioprotective
properties, containing hydrophobic mediator(s) \ 30 kDa
offering cytoprotection via PI3K/Akt-dependent signaling at
ischemic reperfusion.
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Introduction
Impaired coronary circulation caused by a myocardial
ischemic episode will lead to compromised hemodynamic
function and ultimately cell death. Rapid restoration of
coronary blood flow to the infarct-related coronary artery
by thrombolysis or primary coronary angioplasty is
effective interventions for limiting myocardial infarct size
and improving clinical outcomes [20, 39]. Although early
reperfusion is essential to limit infarct size, it may para-
doxically induce cell death (lethal reperfusion injury) [2].
Two ways of protecting the heart against reperfusion-
induced injury are ischemic preconditioning (IPC) [22] and
ischemic postconditioning (IPost) [40], applying transient
non-lethal episodes of myocardial ischemia and reperfu-
sion either before or after the index ischemic event,
respectively. Another strategy for achieving cardioprotec-
tion is remote ischemic preconditioning (RIPC), whereby
brief ischemia in one distant region or organ protects the
heart from a sustained episode of ischemia [26]. Remote
IPost (RIPost) is a more clinically relevant cardioprotec-
tive strategy, and has been shown to be effective in
experimental studies when the remote ischemic
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conditioning was applied after the onset of myocardial
ischemia [15].
There is strong evidence that one or more factors
released in response to brief episodes of ischemia during
IPC can interact with receptors, locally or at a distance,
triggering a cytoprotective response. Dickson et al. [6]
found that IPC-induced cardioprotection could be trans-
ferred between individuals by transfusion of whole blood
from preconditioned to non-preconditioned rabbits and
that effluent from preconditioned isolated ex vivo rabbit
hearts offered protection to non-preconditioned hearts [5].
Furthermore, Serejo et al. [28] recently showed that car-
dioprotective factors released into coronary IPC effluent
from ex vivo rat hearts are thermolabile hydrophobic
substances with molecular weights higher than 3.5 kDa
offering cytoprotection via PKC activation in the recipient
heart. In addition, Lang et al. [17] suggested that media-
tor(s) released during IPC in rat hearts are smaller than
8 kDa.
IPC and IPost reduce infarct size when studied in a
wide variety of experimental models including rat, rabbit,
dog, pig and primates by sharing similar mechanisms and
exerting most of their cytoprotection at reperfusion [9, 12,
26, 37]. IPC activates PI3-kinase which facilitates phos-
phorylation and activation of the protein kinase Akt
through its mediator PDK-1 [1]. Akt is part of the
reperfusion injury salvage kinases (RISK) that confer
cardioprotection when activated at reperfusion [9]. IPost
activates similar signaling pathways to IPC [9] and is
thereby also dependent on RISK activation to exert its
protection [35], although the involvement of RISK has
lately been proven to be species dependent [27, 30]. The
underlying mechanism of RIPC and RIPost remains
unclear, but many of the signaling pathways underlying
myocardial preconditioning and postconditioning have
been implicated in RIPC [11].
Numerous studies have focused on characterizing the
signaling mechanisms involved in IPC. However, the pre-
cise adaptive response triggered by agents released during
the short reperfusion episodes of IPC remains unresolved.
Identification of such mediators would be of great impor-
tance for the development of pharmacological therapies to
enhance myocardial tolerance to ischemia–reperfusion-
induced stress in patients with acute myocardial infarction
(AMI) [38]. The aims of this study were therefore to (1)
investigate the protective capabilities of the IPC effluent
when delivered at ischemic reperfusion and its potential to
induce remote postconditioning (RIPost); (2) determine if
coronary IPC effluent mediates its protection through a
PI3K/Akt-dependent cytoprotective signaling pathway; (3)
characterize the protective mediator(s) by fractionation of
effluent based on different properties such as hydropho-
bicity and size.
Methods
Langendorff perfusion procedure
All experiments were approved by the Norwegian State
Commission for Laboratory Animals, and carried out in
accordance with the European Communities Council
Directive of 1986 (86/609/EEC).
Male Wistar rats (250–350 g, n = 183) fed a standard
diet were heparinized (200 IU) and anesthetized with
sodium pentobarbital (50 mg/kg) i.p. The hearts were
excised, placed in ice-cold Krebs–Heinseleit buffer (KHB)
and rapidly mounted onto a Langendorff perfusion system.
KHB (pH 7.4, oxygenated with 95% O2/5% CO2) con-
tained in mM: 118 NaCl, 4.7 KCl, 1.8 CaCl2, 1.2 KH2PO4,
1.2 MgSO4, 25.2 NaHCO3, 11.0 glucose. Perfusion pres-
sure was maintained at 100 cmH2O, and the myocardial
temperature kept at 37.5C. A water-filled latex balloon,
connected to a hydrostatic pressure transducer (SP844,
Memscap, Norway) and coupled to a high performance
data acquisition system (PowerLab 8/30, Chart Pro soft-
ware-MLS250, Australia), was inserted into the left ven-
tricle and inflated to set an end-diastolic pressure of
5–10 mmHg. Coronary flow (CF) was measured by timed
collection of effluent over 1 min. A 3-0 silk suture was
passed around the main branch of the left coronary artery,
and threaded through a small vinyl tube to form a snare.
Regional ischemia (RI) was achieved by pulling the snare,
and confirmed by a substantial fall in left ventricular
developed pressure (LVDP) and CF.
Experimental protocols
The experimental protocols are shown in Fig. 1. Baseline
values for functional parameters were obtained after
10 min of stabilization. All hearts were subjected to the
ischemia/reperfusion (I/R) protocol consisting of 30 min of
regional ischemia (RI = index ischemia) and 120 min
of reperfusion. The IPC protocol consisted of 39 5 min of
global ischemia (GI) with 5 min intermittent reperfusions
prior to RI. Coronary IPC effluent (*150 ml) was col-
lected during the intermittent reperfusion periods. Fresh
effluent was used for each experiment. Since studies show
that coronary effluent from non-preconditioned hearts does
not influence the infarct size when administered to reci-
pient hearts [28], we did not repeat these experiments in
this study.
Initially, effects of coronary IPC effluent were studied
during two temporal distinct administration periods, before
and after index ischemia (Fig. 1a). IPC effluent was
administered 10 min prior to index ischemia (EffPre) and for
10 min at reperfusion (EffRep). Subsequently, IPC effluent
was administered to simulate ischemic postconditioning
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(RIPost) by perfusing the coronary effluent for 39 30 s at
early reperfusion (EffPost). The ischemic postconditioning
(IPost) protocol consisted of 39 30 s GI intermitted by 30 s
reperfusion periods. Furthermore, to explore if the cardio-
protective properties mediated by the coronary IPC effluent
were dependent on PI3K/Akt-dependent signaling at
reperfusion, the PI3K-inhibitor Wortmannin (WI; 1 lM)
(Tocris Bioscience, UK) and the Akt-inhibitor SH-6
(10 lM) (Enzo Life Sciences, New York, USA) were
administered for 10 min at ischemic reperfusion (EffPre ?
WI/SH-6 and EffRep ? WI/SH-6 and EffPost ? WI;
Fig. 1a). Since WI attenuated the cytoprotective effect of
the effluent administered as a RIPost stimulus, and further
that SH-6 abolished the IPC effluent-induced cardiopro-
tection at reperfusion, we did not include experiments with
effluent RIPost and the SH-6 inhibitor.
To further delineate the properties of putative cytopro-
tective mediator(s) released into collected IPC effluent,
another set of experiments was performed (Fig. 1b).
Firstly, effluent was separated into hydrophilic and
hydrophobic fractions and administered either prior to
ischemia (HPhilPre and HPhobPre) or at reperfusion
(HPhobRep and HPhobPost). The hydrophobic effluent was
further fractionated using spin columns containing cut-off
filters of either 10 or 30 kDa, resulting in four different
fractions that were administered to recipient hearts either
prior to ischemia (HPhobPre \ 10 and HPhobPre [ 10) or at
reperfusion (HPhobRep \ 30 and HPhobRep [ 30).
Fractionation of IPC effluent
Coronary effluent from isolated ex vivo Langendorff per-
fused rat hearts exposed to IPC was collected during the
intermittent reperfusion periods. The effluent was taken
through a series of preparation steps in order to purify
putative mediators of IPC-mediated cardioprotection. C18
solid phase extraction cartridges (Waters Corp., USA) were
conditioned with 6 ml 100% acetonitrile (ACN) followed
by equilibration with 6 ml of ddH2O. Thereafter, IPC
effluent was applied to the cartridge at a flow rate of 1 ml/
min. Following this, the cartridge was washed with 10 ml
water to elute unbound hydrophilic compounds (hydro-
philic fraction). Hydrophobic proteins were eluted with
6 ml of 60% ACN. To remove the organic phase, eluted
sample was evaporated under a stream of nitrogen. The
hydrophobic eluted fraction was then either re-suspended
in KHB for perfusion or re-suspended in ddH2O and sub-
jected to spin columns with either 10 or 30 kDa cut-off
filter (Sartorius Stedim Biotech, France) and thereafter
diluted in KHB (total volume of 150 ml KHB) before
perfusion. All fractions were perfused to untreated reci-
pient hearts for 10 min either prior to index ischemia
(HPhilPre or HPhobPre) or at reperfusion (HPhobRep or
HPhobPost) (Fig. 1b).
Determination of infarct size
At the end of each experiment, the silk suture was securely
tightened and a 0.2% (w/v) Evans Blue solution (Sigma
Chemicals Co., USA) infused to visualize the risk zone.
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Fig. 1 Experimental protocols. All groups were subjected to 30 min
of regional ischemia (RI) followed by 120 min of reperfusion. Hearts
receiving no other treatments constitute the control group (Ctr). a The
IPC group was exposed to 39 5 min global ischemia (GI), with 5 min
intermittent reperfusion periods prior to RI. To test the temporal
cytoprotective efficacy of IPC effluent in recipient hearts, freshly
collected effluent was administered for 10 min prior to RI (EffPre) or
for 10 min at onset of ischemic reperfusion (EffRep). Furthermore, to
mimic ischemic postconditioning, the IPC effluent was administered
for 39 30 s with 30 s intermittent KHB perfusion at immediate
reperfusion (EffPost). Ischemic postconditioning (IPost) was achieved
by 39 30 s of global ischemia (GI) at early ischemic reperfusion. The
PI3K-inhibitor WI (1 lM) and the Akt-inhibitor SH-6 (10 lM) were
administered for 10 min at immediate onset of ischemic reperfusion
in conjunction with 10 min of pre- or post-ischemic treatment with
IPC effluent (EffPre ? WI/SH-6, EffRep ? WI/SH-6 or EffPost ? WI).
b The IPC effluent was fractionated in respect to charge and size.
Effluent collected during IPC was first separated into a hydrophilic
(HPhil) and a hydrophobic (HPhob) fraction. All total effluent
fractions were administered for either 10 min prior to ischemia
(HPhilPre and HPhobPre) or for 10 min at reperfusion (HPhobRep and
HPhobPost). The hydrophobic fraction was further fractionated by a 10
or 30 kDa size filter resulting in four hydrophobic fractions with
molecules below 10/30 kDa (HPhobPre \ 10 and HPhobRep \ 30) or
above 10/30 kDa (HPhobPre [ 10 and HPhobRep [ 30). Arrows
indicate time points for tissue sampling. Solid lines KH buffer
perfusion
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Hearts were thereafter frozen at -20C before being cut
into 2-mm thick slices parallel to the atrioventricular
groove and stained with 1% triphenyl-tetrazolium-chloride
(TTC, Sigma Chemicals Co, USA) in phosphate buffer (pH
7.4) for 20 min at 37C. The slices were then immersed in
4% (v/v) formalin to enhance contrast of the stain, before
being placed between two glass plates and digitalized. Area
at risk (AAR, i.e. area not stained by Evans Blue), live cells
(TTC positive, i.e. red) and infarcted area (TTC negative)
were determined in a blinded fashion using a computerized
planimetry program (Planimetry? v2.0; Erik Traasdahl,
ENK, Norway). Infarct size is presented as the ratio
between the infarcted area and AAR in percent. There were
no significant differences between the different treatment
groups in the relative size of the AAR (volume of area at
risk/volume of left ventricle) (Table 1).
Immunoblot analysis
Levels of Akt (total-Akt, Santa Cruz Biotechnology, Cal-
ifornia, USA) and its phosphorylation at Ser473 (p-Akt, Cell
Signal, Massachusetts, USA) were determined by western
blotting. Heart tissue was harvested at stabilization (control
baseline, CB), at the end of IPC protocol or at 15 min of
reperfusion (time points indicated by arrow in Fig. 1a).
Furthermore, in order to explore the potential of pre-
ischemic effluent administrations ability to modulate Akt
phosphorylation at reperfusion, a separate group for WB
only were administered effluent for 10 min prior to index
ischemia and the tissue harvested after these hearts had
been reperfused for 15 min (EffPre?Rep). At the end of the
experiment, AAR of the left ventricle was excised and snap
frozen in liquid nitrogen. Homogenization of cardiac tis-
sue, protein quantification, sample preparation (40 lg per
lane) and electrophoresis were performed as previously
described [14]. Densitometric analysis was performed
using Quantity One software (Bio-Rad, CA, USA) and
phosphorylation of Akt was expressed as the ratio between
p-Akt and total-Akt. Results normalized against baseline
hearts, CB. GADPH was used as loading control (Santa
Cruz Biotechnology, California, USA).
Statistical analysis
Values are presented as mean ± standard error of the mean
(SEM). Infarct sizes and AAR were tested for group dif-
ferences by one-way analysis of variance (ANOVA)
combined with Fisher’s post hoc test. Comparisons of
LVDP, HR and CF were performed with ANOVA com-
bined with Bonferroni post hoc test. To test for immunoblot
differences, Student’s t test for independent samples was
used. For all tests, P \ 0.05 was considered statistically
significant.
Results
IPC effluent induces remote postconditioning
by reducing infarct size when administered
at reperfusion
Administration of IPC effluent from the onset of reperfu-
sion significantly reduced infarct size in un-preconditioned
recipient hearts compared to controls (EffRep: 25 ± 4% vs.
Ctr: 54 ± 5%, P \ 0.05; Fig. 2). Furthermore, the infarct
size reduction was comparable to that of hearts subjected to
ischemic preconditioning (IPC) or treated with IPC effluent
prior to index ischemia (EffPre) (IPC: 21 ± 2%, EffPre:
24 ± 6% vs. EffRep: 25 ± 4%, ns; Fig. 2).
Table 1 Ratio of volume of area at risk (AAR) and left ventricle
(LV) by Evans Blue staining
Group AAR/LV
Ctr 0.43 ± 0.03
Ctr ? WI 0.53 ± 0.06
Ctr ? SH-6 0.41 ± 0.04
IPC 0.46 ± 0.02
EffPre 0.50 ± 0.03
EffPre ? SH-6 0.48 ± 0.04
EffPre ? WI 0.34 ± 0.03
EffRep 0.39 ± 0.03
EffRep ? SH-6 0.36 ± 0.03
EffRep ? WI 0.47 ± 0.02
IPost 0.52 ± 0.03
EffPost 0.46 ± 0.03
EffPost ? WI 0.43 ± 0.05
HPhilPre 0.42 ± 0.03
HPhobPre 0.43 ± 0.09
HPhobRep 0.39 ± 0.05
HPhobPost 0.36 ± 0.04
HPhobPre \ 10 0.43 ± 0.03
HPhobPre [ 10 0.45 ± 0.02
HPhobRep \ 30 0.45 ± 0.03
HPhobRep [ 30 0.46 ± 0.01
Values represent mean ± SEM
Ctr ischemia–reperfusion controls; IPC ischemic preconditioning, 39
5 min; EffPre/HPhobPre 10 min effluent administration prior to
ischemia; EffRep/HPhobRep 10 min effluent administration at reper-
fusion; IPost ischemic postconditioning, 39 30 s; EffPost/HPhobPost
postconditioning mimetic, 39 30 s; WI 10 min Wortmannin (1 lM);
SH-6 10 min SH-6 (10 lM) at reperfusion; HPhil effluent not bound
to C18 column; HPhob total effluent eluted from C18 column; \ or
[10 or 30 kDa total hydrophobic fraction further separated by size
exclusion column
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In addition, mimicking pharmacological postcondition-
ing by administering IPC effluent to recipient hearts for 39
30 s at onset of reperfusion (RIPost) significantly reduced
infarct size as compared to control hearts (EffPost: 35 ± 3%
vs. Ctr: 54 ± 5%, P \ 0.05; Fig. 3). There was no statistical
difference in infarct size comparing the IPost and EffPost
groups (IPost: 30 ± 5% vs. EffPost: 35 ± 3%, ns; Fig. 3).
Lastly, comparing the infarct sizes in all IPC effluent-
treated groups, it is apparent that the effluent confers
similar degree of cytoprotection independent of whether
treatment was administered before or after the index
ischemic insult (EffPre: 24 ± 6%, EffRep: 25 ± 4% and
EffPost: 35 ± 3%, ns; Figs. 2, 3). Furthermore, coronary
IPC effluent conveys cardioprotection comparable to IPC
hearts, revealing that the putative cytoprotective media-
tor(s) could lead to a very promising therapeutic strategy
for patients being revascularized after AMI.
The cytoprotection offered by IPC effluent
at reperfusion is mediated by PI3K/Akt-dependent
cell-survival signaling in recipient heart
IPC is known to activate the pro-survival kinase Akt directly
after the IPC protocol [34]. Interestingly, administration of
IPC effluent prior to index ischemia caused a significant
increase in Akt phosphorylation compared to hearts exposed
to IPC treatment only (EffPre: 5.2 ± 0.2 AU vs. IPC:
2.0 ± 0.2 AU, P \ 0.05; Fig. 4a, b), indicating an increased
potential of the IPC effluent to activate the pro-survival Akt-
signaling as compared to the IPC stimulus itself. Further-
more, administration of IPC effluent at reperfusion elevated
the Akt-phosphorylation compared to I/R control hearts
(EffRep: 7.2 ± 0.2 AU vs. CtrRep: 2.0 ± 0.5 AU, P \ 0.05;
Fig. 4c, d). Treatment with pre-ischemic IPC effluent and
analysis of Akt phosphorylation at reperfusion (EffPre?Rep)
also increased phosphorylation status of Akt as compared to
the I/R control group (EffPre?Rep: 4.2 ± 0.6 AU vs. CtrRep:
2.0 ± 0.5 AU, P \ 0.05; Fig. 4c, d).
Total Akt or GADPH did not alter during the experi-
ments (Fig. 4a, c), implying that increased relative phos-
phorylation is a result of changes in Akt phosphorylation
and not alterations in the total kinase level or unequal
loading. Exploring the phosphorylation status of STAT-3, a
member of the Survivor Activating Factor Enhancement
(SAFE) pathway [18], we found no regulation (results not
shown).
Hausenloy et al. [9] have previously shown that Akt
phosphorylation at reperfusion is essential for IPC-induced
protection, since inhibition of this kinase during early
reperfusion abrogated the IPC-mediated reduction in
infarct size. Therefore, to elucidate whether IPC effluent
exerts its cardioprotective effect through an PI3K/Akt-
dependent signaling pathway activated at reperfusion,
hearts were administered fresh IPC effluent for 10 min
either prior to index ischemia (EffPre) or at reperfusion
(EffRep or EffPost), and co-administered the PI3K-inhibitor
WI or the Akt-inhibitor SH-6 for 10 min at reperfusion (see
experimental protocol Fig. 1). The protective effect of IPC
effluent was completely abolished by co-administering WI
or SH-6 at reperfusion compared to the EffPre group
(EffPre ? WI: 51 ± 7%, EffPre ? SH-6: 60 ± 4% vs.
EffPre: 24 ± 6%, P \ 0.05; Fig. 5) and the EffRep group
(EffRep ? WI: 56 ± 12%, EffRep ? SH-6: 54 ± 8% vs.
EffRep: 25 ± 4%, P \ 0.05; Fig. 5) and EffPost group
(EffPost ? WI: 50 ± 11% vs. EffPost; 35 ± 3%, P \ 0.05)
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Fig. 2 The temporal effect of treatment with IPC effluent on
myocardial infarct size. Infarct size is expressed as percentage of
the region at risk of infarction (area at risk). Effluent from
preconditioned donor hearts (IPC) administered either 10 min prior
to index ischemia (EffPre) or for 10 min at ischemic-reperfusion
(EffRep) significantly reduced infarct size in non-preconditioned
recipient hearts as compared to controls (Ctr). Bars represent
mean ± SEM. N C 7 in each group. *P \ 0.05 versus Ctr group
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Fig. 3 The effect of administering IPC effluent as a mimetic of
ischemic postconditioning (RIPost) on myocardial infarct size.
Treatment of recipient hearts with IPC effluent for 39 30 s at
ischemic reperfusion (EffPost) reduced infarct size to the same extent
as ischemic postconditioning (IPost), and both groups had signif-
icantly reduced infarct size as compared to the control group (Ctr).
Bars represent mean ± SEM. N C 7 in each group. *P \ 0.05 versus
Ctr
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(data not shown). SH-6 is a phosphatidylinositol (PI) analog
that inhibits Akt without affecting the activity of its
upstream kinase PDK-1 [16], and has also been shown to
prevent phosphorylation of Akt at Ser473 [4, 32]. The
inhibitors themselves had no effect on infarct size (WI:
54 ± 8%, SH-6: 52 ± 3% vs. Ctr: 54 ± 5%, ns). Further-
more, both WI and SH-6 significantly reduced Akt phos-
phorylation in IPC effluent-treated hearts (EffRep ? WI:
0.7 ± 0.1 AU, EffRep ? SH-6: 2.8 ± 0.2 AU vs. EffRep:
7.2 ± 0.2 AU, P \ 0.05; Fig. 4c, d).
Functional parameters are shown in Tables 2 and 3. There
were no major group differences concerning baseline values,
values at the start of RI or at reperfusion (Tables 2, 3).
Cardioprotective potency of fractionated IPC effluent
To further characterize potential humoral factor(s), the
coronary IPC effluent was separated into hydrophilic and
hydrophobic fractions, and the hydrophobic fraction was
further divided based on particulate size ([ or \10 or
30 kDa). The total hydrophobic effluent fraction adminis-
tered for 10 min before hearts were subjected to 30 min of
regional ischemia (HPhobPre) resulted in a significantly
reduced infarct size as compared to hydrophilic fraction-
treated hearts and controls (HPhilPre: 59 ± 4%, Ctr:
54 ± 5% vs. HPhobPre: 28 ± 5%, P \ 0.05; Fig. 6). Fur-
thermore, administration of the total hydrophobic effluent
fraction at ischemic reperfusion also resulted in signifi-
cantly reduced infarct size as compared to controls
(HPhobRep: 29 ± 3%, HPhobPost: 22 ± 4% vs. Ctr:
54 ± 5%, P \ 0.05; Fig. 6). We further fractionated the
hydrophobic IPC effluent into four fractions with particu-
late size [ or \10 or 30 kDa. All fractions below 30 kDa
afforded cardioprotection as compared to control hearts
(HPhobPre \ 10: 27 ± 4%, HPhobPre [ 10: 37 ± 5%,
HPhobRep \ 30: 36 ± 6% vs. Ctr: 54 ± 5%, P \ 0.05;
Fig. 6). However, the cytoprotective mediator in the IPC
effluent appears to be of a size less than 30 kDa as the
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Fig. 4 Phosphorylation status of myocardial Akt in recipient hearts
exposed to treatment with IPC effluent. a Representative immuno-
blots of Akt phosphorylation (Ser473) showing the effects of treatment
with IPC effluent (EffPre) in recipient hearts (tissue harvested at end of
treatment), as compared to hearts exposed to the standard IPC
protocol (IPC) and baseline hearts (CB). c Representative immuno-
blots of Akt phosphorylation (Ser473) in pre-ischemic IPC effluent-
treated hearts that was also reperfused for 15 min (EffPre?Rep) and
reperfusion treatment with IPC effluent (EffRep) in recipient hearts as
compared to ischemic reperfused control hearts (CtrRep) (tissues
harvested at 15 min of reperfusion). Administering the PI3K-inhibitor
WI (1 lM) and the Akt-inhibitor SH-6 (10 lM) for 10 min at
reperfusion abrogated Akt phosphorylation in IPC effluent-treated
hearts. Total Akt and GADPH indicates equal loading. b, d Densito-
metric analysis of total and phosphorylated Akt immunoblots
expressed in arbitrary units (AU). p-Akt expressed as a ratio of total
Akt with CB = 1. Bars represent mean ± SEM. N C 3 in each group.
*P \ 0.05 versus CB,
P \ 0.05 versus IPC, §P \ 0.05 versus
EffPre?Rep,
¤P \ 0.05 versus EffRep,
#P \ 0.05 versus CtrRep
140 Basic Res Cardiol (2011) 106:135–145
123
group with particulate fraction above this size failed to
offer any cardioprotection (HPhobRep [ 30: 52 ± 4% vs.
Ctr: 54 ± 5%, ns).
Discussion
To summarize, our data demonstrate that collected coro-
nary IPC effluent contains humoral factor(s) of a hydro-
phobic character \ 30 kDa in size that offers strong
cytoprotective properties, significantly reducing infarct size
when administered at early ischemic reperfusion in reci-
pient rat hearts, either given as a reperfusion therapy or as
pharmacological mimetic of ischemic postconditioning
(remote IPost). Moreover, these data suggest that this
cardioprotection is partly mediated via PI3K/Akt-depen-
dent cell-survival signaling at ischemic reperfusion.
Our results are in agreement with experiments per-
formed by Serejo et al. [28] and Dickson et al. [5] in the ex
vivo rat and rabbit heart, respectively. These studies
demonstrate that coronary effluent from donor hearts sub-
jected to IPC confers cardioprotection in isolated buffer-
perfused ex vivo recipient hearts administered prior to
index ischemia. However, coronary reperfusion is the only
means of limiting infarct size, provided that it occurs early
after coronary occlusion, but may paradoxically directly
result in tissue injury (lethal reperfusion injury). In order to
explore if collected IPC coronary effluent could reduce
lethal reperfusion-induced injury, we administered IPC
effluent for 10 min at immediate reperfusion. Our results
confirm that IPC effluent limits reperfusion-induced injury
by proving able to offer cytoprotection similar to pre-
ischemic treatment even when administered as reperfusion
therapy (Fig. 2). In order to further evaluate the temporal
requirements of the IPC effluent, it was administered as a
postconditioning stimulant at early reperfusion (experi-
mental protocol, Fig. 1), drastically reducing the total
treatment time and volume. Nevertheless, exposing the
recipient hearts to *85% less effluent over a shorter time
period still offered substantial cardioprotection in un-pre-
conditioned hearts, also validating the phenomena of
remote postconditioning (RIPost).
The study by Serejo et al. [28] indicated that the pro-
tective effect afforded by IPC effluent disappeared when
heated or left in RT for 24 h, while addition of protease
inhibitors prevented this time-dependent break down and
effluent purification by reverse phase chromatography
suggested that the cardioprotective factor(s) could be of a
hydrophobic ‘‘protein nature’’. Our results confirm these
findings as administration of total isolated hydrophobic
fraction prior to index ischemia or at reperfusion, as
reperfusion therapy or RIPost treatment, reduced infarct
size by 35–40% compared to control and hydrophilic
fraction-treated group. Further fractionation of the total
hydrophobic effluent into low and high molecular weight
fractions, with either a 10 or 30 kDa cut-off, revealed that
both 10 kDa fractions, but only the low weight fractions of
30 kDa cut-off, retained the ability to offer cardioprotec-
tion comparable to the cytoprotection afforded by the total
hydrophobic faction (Fig. 6). Thus, we propose that the
factor(s) responsible for the protective capabilities have a
size either under or close to 30 kDa (depending on the
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administration prior to RI; EffRep 10 min effluent administration after
RI; EffPost effluent administration 39 30 s at start of reperfusion; WI
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(10 lM) at reperfusion. Bars represent mean ± SEM. N C 6 in each
group. *P \ 0.05 versus Ctr
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efficiency of the columns used). Since both 10 kDa frac-
tions were protective, this suggests that the effluent either
contains more than one factor with protective capabilities,
with at least one of them being of a smaller and one of a
larger size than the size of the filter used (10 kDa), or that
the factor(s) is of a size close to the columns 10 kDa cut-
off limit, causing it to be present in both fractions.
Adenosine, opioids and bradykinin are endogenously
released triggers of IPC that work in parallel, binding to
Table 2 Functional parameters recorded during the experimental
protocol investigating the temporal effects of administering the IPC
effluent to un-preconditioned recipient hearts
Group 10 min stab 5 min RI 30 min rep 120 min rep
LVDP (mmHg)
Ctr 155 ± 22 87 ± 8# 109 ± 12 78 ± 8#
Ctr ? WI 160 ± 12 73 ± 11# 71 ± 9 67 ± 6#
Ctr ? SH-6 149 ± 17 78 ± 13# 112 ± 9# 84 ± 10#
IPC 160 ± 11 73 ± 7# 98 ± 7# 70 ± 5#
EffPre 171 ± 21 73 ± 14
# 87 ± 2# 67 ± 5#
EffPre ? SH-6 177 ± 17 113 ± 11
# 68 ± 8# 51 ± 3#
EffPre ? WI 148 ± 12 73 ± 9
# 81 ± 7# 66 ± 6#
EffRep 177 ± 9 84 ± 14
# 104 ± 10# 77 ± 9#
EffRep ? SH-6 156 ± 8 103 ± 9
# 93 ± 7# 74 ± 6#
EffRep ? WI 162 ± 17 111 ± 18
# 97 ± 18# 69 ± 13#
IPost 150 ± 10 68 ± 11# 78 ± 9# 59 ± 7#
EffPost 157 ± 19 80 ± 14
# 106 ± 9 61 ± 8#
EffPost ? WI 156 ± 11 99 ± 15
# 94 ± 15# 85 ± 10#
CF (ml/min)
Ctr 13.4 ± 1.7 9.1 ± 1.3# 9.1 ± 0.8# 6.2 ± 0.7#
Ctr ? WI 12.9 ± 0.6 7.3 ± 0.6# 10.5 ± 0.8 7.3 ± 0.6#
Ctr ? SH-6 12.8 ± 0.4 7.9 ± 0.4# 6.2 ± 1.6# 6.1 ± 1.1#
IPC 14.2 ± 0.9 8.0 ± 0.7# 12.1 ± 1.1 7.3 ± 0.9#
EffPre 13.3 ± 0.5 6.9 ± 0.8
# 8.0 ± 0.5# 6.5 ± 0.6#
EffPre ? SH-6 17.2 ± 3.2 8.7 ± 1.2
# 6.8 ± 0.8# 6.2 ± 1.1#
EffPre ? WI 15.8 ± 1.5 7.8 ± 0.8
# 10.8 ± 1.0# 7.1 ± 1.0#
EffPre 13.6 ± 1.0 8.1 ± 1.0
# 10.2 ± 0.4# 7.5 ± 0.4#
EffPre ? SH-6 14.9 ± 0.9 8.9 ± 0.9
# 7.8 ± 0.6# 6.5 ± 0.6#
EffRep ? WI 15.6 ± 0.6 7.6 ± 1.1
# 9.3 ± 1.5# 7.1 ± 1.4#
IPost 12.3 ± 0.8 7.2 ± 0.5# 8.2 ± 0.9# 5.9 ± 0.3#
EffPost 13.8 ± 0.7 8.4 ± 0.6
# 10.4 ± 0.7# 7.6 ± 0.6#
EffPost ? WI 14.1 ± 0.6 8.9 ± 0.8
# 11.4 ± 0.9 8.7 ± 0.4#
HR (beats/min)
Ctr 328 ± 21 294 ± 34 268 ± 31 254 ± 17
Ctr ? WI 300 ± 12 288 ± 12 258 ± 43 293 ± 23
Ctr ? SH-6 318 ± 17 276 ± 16 299 ± 18 246 ± 15
IPC 295 ± 22 283 ± 17 270 ± 13 242 ± 9
EffPre 321 ± 12 278 ± 19 285 ± 15 270 ± 14
EffPre ? SH-6 294 ± 18 250 ± 11 236 ± 11 226 ± 29
EffPre ? WI 297 ± 13 298 ± 25 339 ± 23 289 ± 23
EffRep 275 ± 23 273 ± 15 276 ± 19 268 ± 14
EffRep ? SH-6 256 ± 17 238 ± 17 224 ± 17 236 ± 12
EffRep ? WI 277 ± 32 248 ± 30 261 ± 30 241 ± 28
IPost 298 ± 15 266 ± 13 261 ± 9 233 ± 6
EffPost 280 ± 7 230 ± 16 293 ± 15 239 ± 14
EffPost ? WI 316 ± 16 304 ± 24 301 ± 23 278 ± 33
Values represent mean ± SEM
Ctr ischemia–reperfusion controls; IPC ischemic preconditioning, 39
5 min; EffPre 10 min effluent administration prior to ischemia; EffRep
10 min effluent administration at reperfusion; IPost ischemic postcondi-
tioning, 39 30 s; EffPost effluent postconditioning, 39 30 s; WI 10 min
Wortmannin (1 lM); SH-6 10 min SH-6 (10 lM) at reperfusion
# P \ 0.05 versus Stab
Table 3 Functional parameters recorded during the experimental
protocol investigating the effects of administering fractionated IPC
effluent (charge and size) to un-preconditioned recipient hearts
Group 10 min stab 5 min RI 30 min rep 120 min rep
LVDP (mmHg)
Ctr 155 ± 22 87 ± 8# 109 ± 12 78 ± 8#
HPhilPre 153 ± 9 87 ± 8
# 96 ± 9# 69 ± 9#
HPhobPre 151 ± 6 89 ± 18
# 100 ± 5# 87 ± 5#
HPhobRep 168 ± 20 89 ± 8
# 90 ± 16 71 ± 11#
HPhobPost 143 ± 8 78 ± 8
# 90 ± 5# 73 ± 5#
HPhobPre \ 10 143 ± 15 62 ± 9
# 101 ± 8# 74 ± 7#
HPhobPre [ 10 149 ± 13 81 ± 13
# 111 ± 9 83 ± 7#
HPhobRep \ 30 173 ± 9 83 ± 8
# 107 ± 5# 82 ± 5#
HPhobRep [ 30 160 ± 15 100 ± 13
# 83 ± 6# 64 ± 7#
CF (ml/min)
Ctr 13.2 ± 1.4 8.8 ± 1.2# 8.6 ± 0.8# 5.8 ± 0.7#
HPhilPre 13.6 ± 0.5 8.4 ± 0.8
# 10.2 ± 0.9 7.6 ± 0.8#
HPhobPre 13.7 ± 0.5 8.2 ± 2.4
# 9.9 ± 2.7# 7.9 ± 1.9#
HPhobRep 16.4 ± 0.7 10.6 ± 0.5
# 12.2 ± 1.3 10.4 ± 1.5*,#
HPhobPost 13.2 ± 1.1 7.6 ± 1.0
# 9.7 ± 1.3 7.9 ± 1.1#
HPhobPre \ 10 14.6 ± 1.6 7.4 ± 1.2
# 11.9 ± 1.5# 9.4 ± 1.3#
HPhobPre [ 10 14.3 ± 0.9 7.3 ± 1.0
# 11.5 ± 1.1 8.6 ± 0.8#
HPhobRep \ 30 17.1 ± 1.0 10.0 ± 2.1# 11.8 ± 2.4# 9.7 ± 2.2#
HPhobRep [ 30 15.4 ± 1.1 9.1 ± 0.7
# 10.3 ± 0.9# 8.0 ± 0.7#
HR (beats/min)
Ctr 320 ± 15 291 ± 24 249 ± 23 230 ± 24
HPhilPre 299 ± 13 265 ± 27 257 ± 16 266 ± 16
HPhobPre 306 ± 11 283 ± 15 299 ± 12 265 ± 7
HPhobRep 330 ± 13 312 ± 5 315 ± 11 304 ± 9
HPhobPost 329 ± 26 339 ± 18 334 ± 18 328 ± 17*
HPhobPre \ 10 294 ± 10 264 ± 13 287 ± 15 269 ± 10
HPhobPre [ 10 298 ± 11 274 ± 6 274 ± 8 287 ± 10
HPhobRep \ 30 303 ± 10 272 ± 6 255 ± 28 253 ± 28
HPhobRep [ 30 290 ± 15 273 ± 14 241 ± 19 234 ± 18
Values represent mean ± SEM
Ctr ischemia–reperfusion controls; IPC ischemic preconditioning, 39
5 min; EffPre/HPhobPre 10 min effluent administration prior to ischemia;
EffRep/HPhobRep 10 min effluent administration at reperfusion; IPost
ischemic postconditioning, 39 30 s; EffPost/HPhobPost postconditioning
mimetic, 39 30 s; WI 10 min Wortmannin (1 lM); SH-6 10 min SH-6
(10 lM) at reperfusion. HPhil effluent not bound to C18 column; HPhob
total effluent eluted from C18 column; \ or [10 or 30 kDa total hydro-
phobic fraction further separated by size exclusion column
* P \ 0.05 versus Ctr, # P \ 0.05 vs. Stab
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cell surface receptors initiating the IPC response (reviewed
in [7]). Being released into the circulation, the triggers have
also the potential to protect cells not directly subjected to
IPC [26], which could at least in part explain the phe-
nomenon of remote preconditioning (RIPC), in which
preconditioning of non-cardiac tissue such as skeletal
muscle [24] and kidney [33] will protect the heart from
subsequent ischemic events. The mechanisms behind RIPC
are believed to be shared with IPC and IPost [10], and
include the release of cardioprotective autocoids such as
adenosine [3], nitric oxide [29], activation of innate
immunity [36], activation of RISK signaling [9], and the
inhibition of the mitochondrial permeability transition pore
(mPTP) [13]. Recently, RIPC was also shown to work via
unidentified neurological or humoral pathways [19].
However, emerging evidences suggest that adenosine and
other small molecules involved in IPC protection might not
be responsible for the protective capabilities of the IPC
effluent. Dickson et al. [5] compared adenosine levels in
coronary effluent from preconditioned and control hearts,
and found no difference in mean adenosine concentrations.
They also failed to find a relationship between adenosine
concentration and infarct size [5]. Using a 3.5 kDa dialysis
membrane, Serejo et al. [28] excluded low molecular
weight molecules (adenosine 267.24 Da, opioids
500–800 Da, and bradykinin 1,060.22 Da) without losing
the protective effect. Our study confirms that the IPC
effluent must contain cytoprotective substances larger than
3.5 kDa as the hydrophobic fraction [ 10 kDa resulted in
protection similar to the total hydrophobic and low
molecular fractions. Furthermore, our results also suggest
that smaller size molecules might not be necessary in
evoking the cytoprotective response, since the hydrophobic
fraction [ 10 kDa offered a reduction in infarct size
comparable to the total hydrophobic fraction.
Activation of RISK signaling during reperfusion unites
IPC, IPost and other agents that facilitate cardioprotection
when offered either prior to ischemia or at reperfusion [10],
and prolonging RISK activation by phosphatase inhibition
during reperfusion also offers cytoprotection [8]. Of note,
studies have questioned the importance of RISK in car-
dioprotection by IPost [27, 30] and in gentle reperfusion
[23]. However, Akt is an important mediator of RISK
signaling, and inhibition of the up-stream PI3-kinase with
either Wortmannin or LY 294002 reduced Akt phosphory-
lation and abolished IPC-mediated protection [21, 32]. We
have previously demonstrated that pharmacologically
induced phosphorylation of PI3K/Akt in the first few min of
reperfusion after a sustained ischemic insult is cardiopro-
tective [14]. In the present study, we demonstrate that acti-
vation of Akt-dependent pro-survival signaling at
reperfusion is required for the pre-ischemic IPC effluent-
induced protection. Inhibiting PI3K/Akt-signaling at the
onset of reperfusion in hearts pretreated with IPC effluent
completely abolished the protection (Fig. 5). This PI3K/Akt-
dependent cytoprotection offered by pre-ischemic effluent
treatment was paralleled by a significantly increase in Akt
phosphorylation both pre- and post-ischemia (Fig. 4).
Administration of the effluent as a reperfusion therapy also
resulted in increased Akt-phosphorylation, and the protec-
tion was abolished by PI3K/Akt-signaling inhibition. Taken
together, our data indicate that factor(s) retaining cytopro-
tective properties in IPC effluent are conveying cardiopro-
tection via activation of Akt-dependent signaling that can be
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Fig. 6 The effect of fractionating the IPC effluent based on charge
and size with regard to myocardial infarct size. Pre- or post-ischemic
administration of the total hydrophobic fraction (HPhobPre, HPhobRep
and HPhobPost) and the fractions containing proteins \ or [10 kDa
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significantly reduced infarct size in non-preconditioned recipient
hearts as compared to hydrophilic effluent (HPhil) and control (Ctr)
hearts. The hydrophobic fraction containing proteins [30 kDa
(HPhobRep \ 30) did not offer any cytoprotection. HPhil effluent
not bound to C18 column; HPhob effluent eluted from C18 column;
total entire hydrophobic fraction;\or[10/30 kDa total hydrophobic
fraction further separated by a size exclusion column. Bars represent
mean ± SEM. N C 5 in each group. *P \ 0.05 versus Ctr
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modulated at reperfusion after a lethal ischemic insult. We
could not prove involvement of the SAFE pathway [18],
which is thought to interact with RISK signaling at
reperfusion, as the IPC effluent failed to modulate the
status of STAT3 phosphorylation (results not shown). In
addition to activation of Akt, the IPC effluent has previ-
ously been shown to lose its protective effect when co-
administered with the PKC inhibitor chelerythrine [28].
PKC has been implicated as an early mediator of pre-
conditioning [31], and may contribute to Akt phosphory-
lation at the time of reperfusion [25], and thereby inducing
cardioprotection which may include inhibition of mito-
chondrial permeability transition pore (mPTP) opening
[9].
In conclusion, effluent collected during ischemic pre-
conditioning of ex vivo rat hearts protects untreated reci-
pient hearts from reperfusion-induced injury via a PI3K/
Akt-dependent pathway that can be modulated at ischemic
reperfusion. The IPC effluent has the ability to offer
cytoprotection when administered as a stimulus of remote
postconditioning (RIPost) or as a reperfusion therapy. The
molecules responsible for the effluents protective abilities
are below or close to 30 kDa and at least one of them are
larger than 10 kDa. Furthermore, our results demonstrate
that the effluent or its mediator(s) has a strong cardiopro-
tective action implying a great potential as adjunct reper-
fusion therapy for patients with AMI.
Acknowledgments AKJ was supported with grants from the Nor-
wegian Council on Cardiovascular Diseases, Bergen Medical
Research Foundation, The Meltzer Foundation, Bergen Heart Foun-
dation. LB is funded by the Norwegian Council on Cardiovascular
Diseases. EH is funded by the Research Council of Norway.
Conflict of interest The authors declare that they have no conflict
of interest.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
References
1. Anderson KE, Coadwell J, Stephens LR, Hawkins PT (1998)
Translocation of PDK-1 to the plasma membrane is important in
allowing PDK-1 to activate protein kinase B. Curr Biol
8(12):684–691
2. Braunwald E, Kloner RA (1985) Myocardial reperfusion: a
double-edged sword? J Clin Invest 76(5):1713–1719. doi:10.
1172/JCI112160
3. Cohen MV, Downey JM (2008) Adenosine: trigger and mediator
of cardioprotection. Basic Res Cardiol 103(3):203–215. doi:
10.1007/s00395-007-0687-7
4. Davidson SM, Hausenloy D, Duchen, Yellon DM (2006) Sig-
nalling via the reperfusion injury signalling kinase (risk) pathway
links closure of the mitochondrial permeability transition pore to
cardioprotection. Int J Biochem Cell Biol 38(3):414–419. doi:
10.1016/j.biocel.2005.09.017
5. Dickson EW, Lorbar M, Porcaro WA, Fenton RA, Reinhardt CP,
Gysembergh A, Przyklenk K (1999) Rabbit heart can be ‘‘pre-
conditioned’’ via transfer of coronary effluent. Am J Physiol
277(6 Pt 2):H2451–H2457
6. Dickson EW, Reinhardt CP, Renzi FP, Becker RC, Porcaro WA,
Heard SO (1999) Ischemic preconditioning may be transferable
via whole blood transfusion: preliminary evidence. J Thromb
Thrombolysis 8(2):123–129
7. Downey JM, Davis AM, Cohen MV (2007) Signaling pathways
in ischemic preconditioning. Heart Fail Rev 12(3–4):181–188.
doi:10.1007/s10741-007-9025-2
8. Fan WJ, van Vuuren D, Genade S, Lochner A (2010) Kinases
and phosphatases in ischaemic preconditioning: a re-evaluation.
Basic Res Cardiol 105(4):495–511. doi:10.1007/s00395-010-
0086-3
9. Hausenloy DJ, Tsang A, Yellon DM (2005) The reperfusion
injury salvage kinase pathway: a common target for both ische-
mic preconditioning and postconditioning. Trends Cardiovasc
Med 15(2):69–75. doi:10.1016/j.tcm.2005.03.001
10. Hausenloy DJ, Yellon DM (2007) Preconditioning and postcon-
ditioning: united at reperfusion. Pharmacol Ther 116(2):173–191.
doi:10.1016/j.pharmthera.2007.06.005
11. Hausenloy DJ, Yellon DM (2008) Remote ischaemic precondi-
tioning: underlying mechanisms and clinical application. Car-
diovasc Res 79(3):377–386. doi:10.1093/cvr/cvn114
12. Heusch G, Boengler K, Schulz R (2008) Cardioprotection: nitric
oxide, protein kinases, and mitochondria. Circulation 118(19):
1915–1919. doi:10.1161/CIRCULATIONAHA.108.805242
13. Heusch G, Boengler K, Schulz R (2010) Inhibition of mito-
chondrial permeability transition pore opening: the holy grail of
cardioprotection. Basic Res Cardiol 105(2):151–154. doi:10.
1007/s00395-009-0080-9
14. Jonassen AK, Sack MN, Mjos OD, Yellon DM (2001) Myocar-
dial protection by insulin at reperfusion requires early adminis-
tration and is mediated via Akt and p70s6 kinase cell-survival
signaling. Circ Res 89(12):1191–1198
15. Kerendi F, Kin H, Halkos ME, Jiang R, Zatta AJ, Zhao ZQ, Guyton
RA, Vinten-Johansen J (2005) Remote postconditioning. Brief renal
ischemia and reperfusion applied before coronary artery reperfusion
reduces myocardial infarct size via endogenous activation of
adenosine receptors. Basic Res Cardiol 100(5):404–412. doi:10.
1007/s00395-005-0539-2
16. Kozikowski AP, Sun H, Brognard J, Dennis PA (2003) Novel PI
analogues selectively block activation of the pro-survival serine/
threonine kinase Akt. J Am Chem Soc 125(5):1144–1145. doi:
10.1021/ja0285159
17. Lang SC, Elsasser A, Scheler C, Vetter S, Tiefenbacher CP,
Kubler W, Katus HA, Vogt AM (2006) Myocardial precondi-
tioning and remote renal preconditioning–identifying a protective
factor using proteomic methods? Basic Res Cardiol 101(2):
149–158. doi:10.1007/s00395-005-0565-0
18. Lecour S, Suleman N, Deuchar GA, Somers S, Lacerda L,
Huisamen B, Opie LH (2005) Pharmacological preconditioning
with tumor necrosis factor-alpha activates signal transducer and
activator of transcription-3 at reperfusion without involving
classic prosurvival kinases (Akt and extracellular signal-regulated
kinase). Circulation 112(25):3911–3918. doi:10.1161/CIRCULA
TIONAHA.105.581058
19. Lim SY, Yellon DM, Hausenloy DJ (2010) The neural and
humoral pathways in remote limb ischemic preconditioning.
Basic Res Cardiol. doi:10.1007/s00395-010-0099-y
20. Miura T, Miki T (2008) Limitation of myocardial infarct size in
the clinical setting: current status and challenges in translating
144 Basic Res Cardiol (2011) 106:135–145
123
animal experiments into clinical therapy. Basic Res Cardiol
103(6):501–513. doi:10.1007/s00395-008-0743-y
21. Mocanu MM, Bell RM, Yellon DM (2002) PI3 kinase and not
p42/p44 appears to be implicated in the protection conferred by
ischemic preconditioning. J Mol Cell Cardiol 34(6):661–668. doi:
10.1006/jmcc.2002.2006
22. Murry CE, Jennings RB, Reimer KA (1986) Preconditioning with
ischemia: a delay of lethal cell injury in ischemic myocardium.
Circulation 74(5):1124–1136
23. Musiolik J, van Caster P, Skyschally A, Boengler K, Gres P, Schulz
R, Heusch G (2009) Reduction of infarct size by gentle reperfusion
without activation of reperfusion injury salvage kinases in pigs.
Cardiovasc Res 85(1):110–117. doi:10.1093/cvr/cvp271
24. Oxman T, Arad M, Klein R, Avazov N, Rabinowitz B (1997)
Limb ischemia preconditions the heart against reperfusion
tachyarrhythmia. Am J Physiol 273(4 Pt 2):H1707–H1712
25. Ping P, Zhang J, Cao X, Li RC, Kong D, Tang XL, Qiu Y,
Manchikalapudi S, Auchampach JA, Black RG, Bolli R (1999)
PKC-dependent activation of p44/p42 MAPKs during myocardial
ischemia-reperfusion in conscious rabbits. Am J Physiol 276(5 Pt
2):H1468–H1481
26. Przyklenk K, Bauer B, Ovize M, Kloner RA, Whittaker P (1993)
Regional ischemic ‘preconditioning’ protects remote virgin
myocardium from subsequent sustained coronary occlusion.
Circulation 87(3):893–899
27. Schwartz LM, Lagranha CJ (2006) Ischemic postconditioning
during reperfusion activates Akt and Erk without protecting
against lethal myocardial ischemia-reperfusion injury in pigs. Am
J Physiol Heart Circ Physiol 290(3):H1011–H1018. doi:10.
1152/ajpheart.00864.2005
28. Serejo FC, Rodrigues LF Jr, da Silva Tavares KC, de Carvalho
AC, Nascimento JH (2007) Cardioprotective properties of
humoral factors released from rat hearts subject to ischemic
preconditioning. J Cardiovasc Pharmacol 49(4):214–220. doi:
10.1097/FJC.0b013e3180325ad9
29. Shiva S, Gladwin MT (2009) Nitrite mediates cytoprotection
after ischemia/reperfusion by modulating mitochondrial function.
Basic Res Cardiol 104(2):113–119. doi:10.1007/s00395-
009-0009-3
30. Skyschally A, van Caster P, Boengler K, Gres P, Musiolik J,
Schilawa D, Schulz R, Heusch G (2009) Ischemic postconditioning
in pigs: no causal role for risk activation. Circ Res 104(1):15–18.
doi:10.1161/CIRCRESAHA.108.186429
31. Speechly-Dick ME, Mocanu MM, Yellon DM (1994) Protein
kinase C. Its role in ischemic preconditioning in the rat. Circ Res
75(3):586–590
32. Stojanovic A, Marjanovic JA, Brovkovych VM, Peng X, Hay N,
Skidgel RA, Du X (2006) A phosphoinositide 3-kinase-Akt-nitric
oxide-cGMP signaling pathway in stimulating platelet secretion
and aggregation. J Biol Chem 281(24):16333–16339. doi:
10.1074/jbc.M512378200
33. Takaoka A, Nakae I, Mitsunami K, Yabe T, Morikawa S, Inu-
bushi T, Kinoshita M (1999) Renal ischemia/reperfusion remo-
tely improves myocardial energy metabolism during myocardial
ischemia via adenosine receptors in rabbits: effects of remote
preconditioning. J Am Coll Cardiol 33(2):556–564
34. Tong H, Chen W, Steenbergen C, Murphy E (2000) Ischemic
preconditioning activates phosphatidylinositol-3-kinase upstream
of protein kinase c. Circ Res 87(4):309–315
35. Tsang A, Hausenloy DJ, Mocanu MM, Yellon DM (2004)
Postconditioning: a form of ‘‘modified reperfusion’’ protects the
myocardium by activating the phosphatidylinositol 3-kinase-Akt
pathway. Circ Res 95(3):230–232. doi:10.1161/01.RES.
0000138303.76488.fe
36. Valeur HS, Valen G (2009) Innate immunity and myocardial
adaptation to ischemia. Basic Res Cardiol 104(1):22–32. doi:
10.1007/s00395-008-0756-6
37. Yang XM, Liu Y, Tandon N, Kambayashi J, Downey JM, Cohen
MV (2009) Attenuation of infarction in cynomolgus monkeys:
preconditioning and postconditioning. Basic Res Cardiol
105(1):119–128. doi:10.1007/s00395-009-0050-2
38. Yellon DM, Downey JM (2003) Preconditioning the myocar-
dium: from cellular physiology to clinical cardiology. Physiol
Rev 83(4):1113–1151. doi:10.1152/physrev.00009.2003
39. Yellon DM, Hausenloy DJ (2007) Myocardial reperfusion injury.
N Engl J Med 357(11):1121–1135. doi:10.1056/NEJMra071667
40. Zhao ZQ, Corvera JS, Halkos ME, Kerendi F, Wang NP, Guyton
RA, Vinten-Johansen J (2003) Inhibition of myocardial injury by
ischemic postconditioning during reperfusion: comparison with
ischemic preconditioning. Am J Physiol Heart Circ Physiol
285(2):H579–H588. doi:10.1152/ajpheart.01064.2002
Basic Res Cardiol (2011) 106:135–145 145
123
